SEC Form 6-K filed by Ping An Biomedical Co. Ltd.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of January, 2026

Commission File Number: 001-42155

22/F, China United Plaza, 1002-1008, Tai Nan West Street,

Cheung Sha Wan, Kowloon, Hong Kong

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒         Form 40-F ☐

Press Release

On January 9, 2026, Ping An Biomedical Co., Ltd. (the “Company”) issued two press releases. The first press announces entering into a series of share purchase agreements with several investors, and is filed as exhibit 99.1 to this Form 6-K. The second press announces the Company’s Strategic Investment in Future Biotechnology Group and is filed as exhibit 99.2 to this Form 6-K.

The foregoing descriptions of the press releases do not purport to be complete and are qualified in their entirety by reference to the respective press releases, which are filed as Exhibit 99.1 and Exhibit 99.2.

Financial Statements and Exhibits.

The following exhibits are being filed herewith:

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.